


Clerk of the House of Representatives Legislative Resource Center B-106 Cannon Building Washington, DC 20515

Secretary of the Senate Office of Public Records 232 Hart Building Washington, DC 20510



01 PEB 14 PM 2: 03

## LOBBYING REPORT

Lobbying Disclosure Act of 1995 (Section 5) - All Filers Are Required To Complete This Page

Bennett, Turner & Coleman, LLP  2. Address			
3. Principal Place of Business (if different from line 2)  City: State/Zip (or Country)  4. Conset Name Telephone Albert Cacozza 202-833-4500  7. Client Name Self AstraZeneca LP  TYPE OF REPORT 8. Year 2000 Midyear (January I-June 30) OR Year End (July I-December 31) Check if this filling amends a previously filed version of this report 0. Check if this filling amends a previously filed version of this report 0. Check if this filling amends a previously filed version of this report 11. No Lobbying Activity 11. No Lobbying Activity 12. Lobbying Firms 13. Organizations 1NCOME OR EXPENSES - Complete Either Line 12 OR Line 13  12. Lobbying Firms 13. Organizations 13. Organizations 14. REPORTING METHOD. Check box to indicate expense period were: Less than \$10,000 14. REPORTING METHOD. Check box to indicate expense activities on behalf of the client).  Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts using LDA definitions only Method C. Reporting amounts usi	E. Registrant Name Bennett, Turner & Coleman, LLP		**************************************
City: State/Zip (or Country)  4. Constat Name Telephone E-mail (optional)  5. Senste 1D #  Albert Cacozza 202-833-4500  7. Client Name Self AstraZeneca LP  TYPE OF REPORT 8. Year 2000 Midyear (January 1-June 30) OR Year End (July 1-December 31) OR Check if this filling amends a previously filed version of this report On Check if this is a Termination Report On Termination Date  11. No Lobbying Activity On Check if this is a Termination Report On Termination Date  12. Lobbying Firms  13. Organizations  EXPENSES relating to lobbying activities for this reporting period was:  13. Organizations  EXPENSES relating to lobbying activities for this reporting period were:  Less than \$10,000 On more On Second		hington, DC 20006	;
Albert Cacozza  202-833-4500  7. Client Name    Self	3. Principal Place of Business (if different from line 2)		
Albert Cacozza  202-833-4500  7. Client Name			
AstraZeneca LP  TYPE OF REPORT 8. Year 2000 Midyear (January I-June 30) OR Year End (July I-December 31) OR Check if this filing amends a previously filed version of this report  0. Check if this filing amends a previously filed version of this report  11. No Lobbying Activity  11. No Lobbying Activity  12. Lobbying Firms 13. Organizations  INCOME OR EXPENSES - Complete Either Line 12 OR Line 13  12. Lobbying Firms 13. Organizations  EXPENSES relating to lobbying activities for this reporting period was:  Less than \$10,000 D  \$10,000 or more Superior Control of this reporting period were:  Less than \$10,000 D  \$10,000 or more Superior Control of Options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  4. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  5. Method B. Reporting amounts under section 6033(b)(8) of the Internal Revenue Code  5. Method B. Reporting amounts under section 162(e) of the Internal Revenue Code	4. Contact Name Telephone	E-mail (optional)	5. Senate 10 #
AstraZeneca LP  TYPE OF REPORT 8. Year 2000   Midyear (January 1-June 30)   OR Year End (July 1-December 31)   Check if this filing amends a previously filed version of this report   Check if this is a Termination Report   Or Termination Date   11. No Lobbying Activity    INCOME OR EXPENSES - Complete Either Line 12 OR Line 13  12. Lobbying Firms   13. Organizations   INCOME relating to lobbying activities for this reporting period was:  Less than \$10,000   Or more   Organizations   Stypenses (nearest \$20,000)   Organizations   Stypenses (nearest \$20,000)   Organizations   I. REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.   Organizations   Organizations   I. Reporting METHOD. Check box to indicate expense accounting method. See instructions for description of options.   Organizations   Organizations   Organizations   Organizations   EXPENSES relating to lobbying activities for this reporting period were: Less than \$10,000   Organizations   Org	Albert Cacozza 202-833-4500	0	
Check if this filing amends a previously filed version of this report  C. Check if this is a Termination Report	7. Client Name 🕒 seif AstraZeneca LP		6. House ID #
12. Lobbying Firms  13. Organizations  INCOME relating to lobbying activities for this reporting period was:  Less than \$10,600	Check if this filing amends a previously filed version of this	report 🖟	ind (July 1-December 31)
INCOME relating to lobbying activities for this reporting period was:  Loss than \$10,600  Less than \$10,600  Less than \$10,000 or more	INCOME OR EXPENSES - Complete Either	Line 12 OR Line 13	
Description was:    Less than \$10,000	12. Lobbying Firms	13. Organiza	tions
\$10,000 or more     Signature			ities for this reporting .
Signature    Sample	Loss than \$10,500 CD	Less than \$10,000 🗍	
Income (nearest \$20,006)  Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying sotivities on behalf of the client).  A REPORTING METHOD. Check box to indicate expense accounting method. See instructions for description of options.  Method A. Reporting amounts using LDA definitions only Method B. Reporting amounts under section 6033(b)(8)of the Internal Revenue Code  Method C. Reporting amounts under section 162(c) of the Internal Revenue Code  Signature  Printed Name and Title  Terry S. Coleman, Partner		\$10,000 or more 🔘 🖘 s 🖵	
Signature Printed Name and Title Terry S. Coleman, Partner	Provide a good faith estimate, rounded to the nearest \$20,000, of all lobbying related income from the client (including all payments to the registrant by any other entity for lobbying	14. REPORTING METHOD. Check accounting method. See instructions for Method A. Reporting amounts us.  Method B. Reporting amounts us.	k box to indicate expense or description of options. ing LDA definitions only ider section 6033(b)(8)of the
Printed Name and Title Terry S. Coleman, Partner			
	Signature		
LD-2 (REV. 6/98) PAGE 1 of	Printed Name and Title Terry S. Coleman, Partner		
	LD-2 (REV. 6/98)		PAGE 1 of 2

Registrant Name Bennett, Turner & Coleman, LLP Client N	AstraZeneca LP
LOBBYING ACTIVITY. Select as many codes as necession engaged in lobbying on behalf of the client during the report information as requested. Attach additional page(s) as need	ting period. Using a separate page for each code, provide
15. General issue area code MMM (one per page)	·
16. Specific lobbying issues  Medicare reimbursement for oral anti-cancer de	ngs
17. House(s) of Congress and Federal agencies contacted U.S. House of Representatives U.S. Senate	Check if None
18. Name of each individual who acted as a lobbyist in this	S issue area  Covered Official Position (if applicable)  New
Sam Turner, Partner	
Elizabeth Goss, Partner	
1778A7937611111111111111111111111111111111111	
<u> </u>	<u> </u>
·	
	ū
PLC will benefit. AstraZeneca PLC is the parent compar success of its subsidiary.  Signature July Column	line 16 above Check if None ons, commercially benefit AstraZeneca LP, so too AstraZeneca ny of AstraZeneca LP and the parent benefits in the commercial  Date February 13, 2001
Printed Name and Title Terry S. Coleman, Partner	
Form LD-2 (Rev.6/98)	than 7 of 7